Ongoing phase 2 and 3 clinical trials in SMM
| . | Phase . | Intervention . | Primary outcome . |
|---|---|---|---|
| DETER-SMM (NCT03937635) | 3 | Daratumumab plus Rd vs Rd | OS, functional assessment score |
| ITHACA (NCT04270409) | 3 | Isatuximab plus Rd vs Rd | Safety, Cmax of isatuximab, PFS |
| AQUILA (NCT03301220) | 3 | SQ daratumumab vs active monitoring | PFS |
| HO147SMM (NCT03673826) | 2 | KRd vs Rd | PFS |
| NCT04776395 | 2 | Iberdomide and dexamethasone vs iberdomide montherapy | ORR |
| PRISM (NCT04775550) | 2 | Daratumumab plus bortezomib and Rd | MRD negativity at 2 y |
| E-PRISM (NCT02279394) | 2 | Elotuzumab plus Rd | PFS at 2 y |
| . | Phase . | Intervention . | Primary outcome . |
|---|---|---|---|
| DETER-SMM (NCT03937635) | 3 | Daratumumab plus Rd vs Rd | OS, functional assessment score |
| ITHACA (NCT04270409) | 3 | Isatuximab plus Rd vs Rd | Safety, Cmax of isatuximab, PFS |
| AQUILA (NCT03301220) | 3 | SQ daratumumab vs active monitoring | PFS |
| HO147SMM (NCT03673826) | 2 | KRd vs Rd | PFS |
| NCT04776395 | 2 | Iberdomide and dexamethasone vs iberdomide montherapy | ORR |
| PRISM (NCT04775550) | 2 | Daratumumab plus bortezomib and Rd | MRD negativity at 2 y |
| E-PRISM (NCT02279394) | 2 | Elotuzumab plus Rd | PFS at 2 y |
SQ, subcutaneous.